Davidson Trust Co. Has $3.29 Million Stock Position in Johnson & Johnson $JNJ

Davidson Trust Co. reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 3.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 21,530 shares of the company’s stock after selling 764 shares during the quarter. Johnson & Johnson makes up about 1.5% of Davidson Trust Co.’s portfolio, making the stock its 15th largest holding. Davidson Trust Co.’s holdings in Johnson & Johnson were worth $3,289,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. GFG Capital LLC acquired a new stake in Johnson & Johnson in the second quarter worth $35,000. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the first quarter valued at $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the first quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the first quarter valued at $52,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on JNJ shares. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 10th. Argus set a $210.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Raymond James Financial raised their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, UBS Group raised their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $199.59.

Johnson & Johnson Stock Up 0.3%

JNJ opened at $191.79 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company’s 50-day moving average is $180.09 and its 200 day moving average is $164.52. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The firm has a market capitalization of $461.90 billion, a P/E ratio of 18.51, a PEG ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion for the quarter. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is currently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.